Study on Raltitrexed with Chemotherapy for Stomach Cancer
Author Information
Author(s): Eatock M M, Anthony D A, El-Abassi M, Wilson P, Paul J, Smith M, Soukop M, Evans T R J
Primary Institution: CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, UK
Hypothesis
Can raltitrexed combined with cisplatin and epirubicin reduce morbidity in advanced gastro-oesophageal adenocarcinoma treatment?
Conclusion
The study found that raltitrexed combined with epirubicin and cisplatin is an effective treatment for advanced gastro-oesophageal adenocarcinoma, with a recommended dose of 2.5 mg/m².
Supporting Evidence
- The study included 24 patients with advanced gastro-oesophageal adenocarcinoma.
- The maximum tolerated dose of tomudex was determined to be 2.5 mg/m².
- The overall response rate was 38%, with eight partial and one complete response.
- The median survival for patients was 9.9 months.
Takeaway
This study tested a new cancer treatment to see if it could help people with stomach cancer feel better while getting chemotherapy.
Methodology
Twenty-four patients received different doses of raltitrexed along with standard chemotherapy drugs to find the maximum tolerated dose and assess toxicity.
Limitations
The study had a small sample size and focused only on specific doses of raltitrexed.
Participant Demographics
22 males and 2 females, median age 63 years, with unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website